ImmuPharma plc (AIM:IMM)

ImmuPharma Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	0.12	0.13
Revenue Growth (YoY)	-	-	-	-6.57%	62.55%
Gross Profit	-	-	-	0.12	0.13
Selling, General & Admin	1.03	1.02	0.85	1.01	1.76
Research & Development	1.16	2.02	2.02	3.65	2.37
Other Operating Expenses	0.39	-0.12	-	-	-
Operating Expenses	2.68	3.06	3.03	5.28	5.72
Operating Income	-2.68	-3.06	-3.03	-5.16	-5.59
Interest Expense	-0	-0	-0	-0.12	-0.23
Interest & Investment Income	0.01	0	0	0	0.04
Currency Exchange Gain (Loss)	-0.15	-0	-0.02	0	-0.15
Other Non Operating Income (Expenses)	0.04	-0.35	-1.41	-2.23	-1.32
EBT Excluding Unusual Items	-2.78	-3.42	-4.46	-7.51	-7.25
Other Unusual Items	-	-	-	-1.43	-
Pretax Income	-2.78	-3.42	-4.46	-8.94	-7.25
Income Tax Expense	-0.3	-0.5	-0.65	-0.77	-0.39
Net Income	-2.48	-2.92	-3.81	-8.17	-6.86
Net Income to Common	-2.48	-2.92	-3.81	-8.17	-6.86
Shares Outstanding (Basic)	416	362	303	251	200
Shares Outstanding (Diluted)	416	362	303	251	200
Shares Change (YoY)	15.04%	19.51%	20.60%	25.47%	30.45%
EPS (Basic)	-0.01	-0.01	-0.01	-0.03	-0.03
EPS (Diluted)	-0.01	-0.01	-0.01	-0.03	-0.03
Free Cash Flow	-1.77	-1.36	-2.45	-4.88	-3.69
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.02	-0.02
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-4359.84%	-4412.70%
Profit Margin	-	-	-	-6906.55%	-5415.72%
Free Cash Flow Margin	-	-	-	-4126.83%	-2912.91%
EBITDA	-2.61	-3.03	-2.91	-5.05	-5.42
D&A For EBITDA	0.06	0.04	0.12	0.11	0.17
EBIT	-2.68	-3.06	-3.03	-5.16	-5.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.